Table 5.

Cumulative incidences of graft loss, rejection, and dnDSA.

Adverse outcomes	Anti-HLA ab (non-DSA)		No anti-HLA ab n = 509	P-value
	Shared TE-positive	Shared TE-negative
	n = 40	n = 29
Functional, n(%)
5y graft loss	3 (7.5)	0 (0)	19 (3.7)	0.27
5y death censored graft loss	3 (7.5)	0 (0)	14 (2.8)	0.15
Immunological, n (%)
5y antibody-mediated rejection	0 (0)	0 (0)	8 (1.6)	0.58
5y T cell-mediated rejection	2 (5)	1 (3.4)	29 (5.7)	0.87
5y dnDSA*	8 (20)	0 (0)	42 (8.3)	0.009
3y dnDSA*	7 (17.5)	0 (0)	31 (6.0)	0.007
2y dnDSA*	7 (17.5)	0 (0)	17 (3.3)	<0.001
1y dnDSA*	4 (10)	0 (0)	10 (2.0)	0.004

*Accumulating number of dnDSA-detected patients during each observational period, which include both persisting and disappearing dnDSA.

Ab, antibody; non-DSA, non-donor-specific anti-HLA antibodies; TE, T cell epitope; 5/3/2/1y, 5/3/2/1-year; dnDSA, de novo donor-specific anti-HLA antibodies.